Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20837912 | 0.98 | PNMT (0.36) | PNMTUSP2FKBP5CRBNHPGD | |
| SCHEMBL13498 | 0.93 | — | — | |
| SCHEMBL6989045 | 0.84 | — | — | |
| SCHEMBL9038503 | 0.72 | USP2 (0.44) | USP2FKBP5CRBN | |
| SCHEMBL9038779 | 0.71 | RAB9A (0.51) | USP2FKBP5CRBNHPGDKDM4E | |
| SCHEMBL6512096 | 0.70 | PNMT (0.47) | PNMT | |
| SCHEMBL2048095 | 0.69 | — | — | |
| SCHEMBL23142283 | 0.68 | PNMT (0.73) | PNMTUSP2 | |
| SCHEMBL14181104 | 0.68 | PNMT (0.41) | PNMTFKBP5CRBN | |
| SCHEMBL3048551 | 0.67 | HPGD (0.50) | CRBNHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2021-06-03 | — | — | US | disclosed |
| EP-3798220-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Shanghai Zhimeng Biopharma, Inc. (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-10626126-B2 | Compounds | PULMOCIDE LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-10626126-B2 | Compounds | PULMOCIDE LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| EP-3245198-B1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190092791-A1 | COMPOUNDS | PULMOCIDE LIMITED (GB) | 2019-03-28 | — | — | US | disclosed |
| US-20190092791-A1 | COMPOUNDS | PULMOCIDE LIMITED (GB) | 2019-03-28 | — | — | US | disclosed |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| WO-2002083685-A1 | CYCLOHEXYLPHENYL VASOPRESSIN AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| US-5719278-A | TREATING EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0811008-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-12-10 | — | — | EP | disclosed |
| US-5696112-A | TREATMENT OF CONGESTIVE HEART FAILURE, CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0804440-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5654297-A | CONGESTIVE HEART FAILURE, CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996022295-A9 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626126-B2 | Compounds | QDPR, TXNRD2, TXNRD3 | PNMT 1000/4885USP2 2906/4885FKBP5 2305/4885 |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | AGTR2, AGTR1, ACE2 | PNMT 464/4885USP2 2412/4885FKBP5 343/4885 |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | PNMT 146/4885USP2 4196/4885FKBP5 2329/4885 |
| US-20190092791-A1 | COMPOUNDS | QDPR, TXNRD2, TXNRD3 | PNMT 1000/4885USP2 2906/4885FKBP5 2305/4885 |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | PNMT 146/4885USP2 4196/4885FKBP5 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.